Anthracyclines News and Research

RSS
Survival rate is improving in HER2 positive breast cancer patients

Survival rate is improving in HER2 positive breast cancer patients

Abnormality on chromosome 17 helps detect breast cancer tumour's response to anthracyclines

Abnormality on chromosome 17 helps detect breast cancer tumour's response to anthracyclines

SpePharm Holding acquires global rights to Savene from TopoTarget

SpePharm Holding acquires global rights to Savene from TopoTarget

Researchers identify new gene signature that predicts cancer recurrence in certain breast tumors

Researchers identify new gene signature that predicts cancer recurrence in certain breast tumors

CytRx announces its plans to advance multiple oncology development programs in 2010

CytRx announces its plans to advance multiple oncology development programs in 2010

Trabectedin now available for patients with advanced soft tissue sarcoma

Trabectedin now available for patients with advanced soft tissue sarcoma

INS cites FDA-approved Totect antidote for anthracycline extravasations

INS cites FDA-approved Totect antidote for anthracycline extravasations

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

Results from CytRx's Phase 2 STAR-1 registration clinical trial for tamibarotene announced

Results from CytRx's Phase 2 STAR-1 registration clinical trial for tamibarotene announced

Updated results from phase III EXTEND clinical trial of pixantrone released

Updated results from phase III EXTEND clinical trial of pixantrone released

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

Cell Therapeutics submits Pediatric Investigation Plan to EMEA for pixantrone

Cell Therapeutics submits Pediatric Investigation Plan to EMEA for pixantrone

Cytrx initiates tamibarotene and TRISENOX combination dose escalation study

Cytrx initiates tamibarotene and TRISENOX combination dose escalation study

FDA approves APP Pharmaceuticals' Idarubicin HCI injection

FDA approves APP Pharmaceuticals' Idarubicin HCI injection

Combining two chemotherapy drugs with Herceptin shows promise for metastatic HER2+ breast cancer

Combining two chemotherapy drugs with Herceptin shows promise for metastatic HER2+ breast cancer

Gene alterations associated with response to anthracycline therapy for breast cancer

Gene alterations associated with response to anthracycline therapy for breast cancer

Researchers show how anthracycline class of chemotherapeutics block blood vessel growth, slow cancer spread

Researchers show how anthracycline class of chemotherapeutics block blood vessel growth, slow cancer spread

Doxil and docetaxel combination treatment delays disease progression in metastatic breast cancer

Doxil and docetaxel combination treatment delays disease progression in metastatic breast cancer